CME: Migraine headaches: Highlights from the American Academy of Neurology 2017 Annual Meeting (AAN 2017)
ACCREDITATION EXPIRED: September 22, 2019
Activity Description / Statement of Need:
In this online CME self-learning program:
Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. It is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. The condition has been identified as one of the most common neurological disorders, and in the United States, its prevalence in the general population is approximately 12%.1 In children, the prevalence ranges from 1% to 4% and does not present more commonly in either sex. However, after menarche, its prevalence in females (18%) is approximately three times higher than in males.
Moreover, professional guidelines relating to the classification, diagnosis, prophylaxis, and treatment of migraine headaches have been updated recently, and communicating related information to healthcare professionals in a timely manner is a demonstrated need. The literature suggests that practicing healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming. Generalists may be at particular risk for missing updates in in standards relating to migraine subtypes like menstual and abdominal migraines.
Agenda:
|
- Faculty member introduction, disclosures |
|
- Major findings from AAN 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) |
|
- Predicted of applicability to clinical practice and patient cases, where relevant |
|
-Concluding remarks |
Target Audience:
Neurologists and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with Migraine
This program is supported by an educational grant from Amgen and Avanir.
Release Date: September 22, 2017 -- Expiration Date: September 22, 2019
Faculty: J. Mark Bailey, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at AAN 2017 relating to migraine and its complications (inclusive of disease diagnosis, progression, prognosis), and apply them to patient cases.
- Summarize the most impactful findings presented at AAN 2017 relating to migraine and its complications (inclusive of evaluation of degree therapeutic success, quantifying benefit and risk of disease progression), and apply them to patient cases.
- Summarize the most impactful findings presented at AAN 2017 relating to migraine and its complications (inclusive of therapeutic, and emerging therapies), and apply them to patient cases.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Mark Bailey, MD has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen and Avanir.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Updates in Migraine Headaches: Best practices and Emerging Therapies in Treatment and Prevention